A New Contender in the Diabetes Drug Arena
Federal Practitioner. 2010 April;27(4):E3
April 1, 2010|Federal Practitioner
Author and Disclosure Information
A new drug, liraglutide (Victoza; Novo Nordisk, Bagsvaerd, Denmark), has been approved by the FDA as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. As a glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide imitates endogenous human GLP-1 to encourage postmeal insulin production by the pancreas. It also delays gastric emptying.
